What is it about?
Explore the optimal tumor burden for starting lenvatinib for differentiated thyroid cancer
Featured Image
Why is it important?
Timing to start lenvatinib for differentiated thyroid cancer is still the matter for debate.
Read the Original
This page is a summary of: Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer, Frontiers in Oncology, July 2021, Frontiers,
DOI: 10.3389/fonc.2021.638123.
You can read the full text:
Contributors
The following have contributed to this page
